Business
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®\nPR Newswire\nMONTREAL, Oct. 5, 2021\n\n\n\nAgreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs Private payer health plan coverage exceeds 85% across Canada Scientific community demonstrates growing interest in both products MONTREAL, Oct. 5, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent (\"LOI\") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies.\n\n\n\"The successfull conclusion of our negotiations with pCPA regarding Enerzair and Atectura is a key milestone for our respiratory commercial program. We now look forward to working diligently with all participating jurisdictions to secure coverage from publicly funded drug plans across Canada. In addition, private payer health plan  coverage currently stands in excess of 85%  of privately insured lives in Canada\", said Frederic Fasano, Valeo's President and Chief Operating Officer. \"As expected, the feedback gathered by our commercial team from healthcare professionals since launching these two innovative asthma drugs is very positive. The large phase III PLATINUM program is continuously delivering further endpoint analyses which are strengthening the clinical profile of both products. We are convinced that the clinical value propositions of Enerzair Breezhaler and Atectura Breezhaler will help expedite provincial public coverage to the benefits of asthma sufferers across Canada\".\nEstablished in August...